Abstract: Objective Radiotherapy has been of key importance to the treatment of malignant gliomas for decades, and the ability to focus the beam and tailor it to the irregular contours of brain tumors and minimize the dose to nearby critical structures with intensity modulated or image-guided techniques has improved greatly. Temozolomide, an alkylating agent given in simple oral route of administration,is used in conjunction with and after radiotherapy. This study aimed to evaluate the toxic effects of temozolomide when used incombination with radiotherapy, to observe the side effects of temozolomide, evaluate the clinical safety of the drug, and improve the quality of life in patients with glioma.Methods Based on the Common Terminology Criteria forAdverse Events (CTCAE) Version 4.0, the authors observed the toxicity of temozolomide in patients with concurrent chemoradiotherapy, and take active measures to deal with the toxicity. Results here were 95 patients who received concurrent chemoradiotherapy, 20 patients had the symptoms of nausea, vomiting and loss of appetite, according to CTCAE-V4.0, 12 cases were grade 1, 8 cases were grade 2. 9 patients had neutropenia, 6 of them were grade 1, 3 cases were grade 2. In the aspect of thrombocytopenia, 3 cases were grade 1, 1 case was grade 2. Mucocutaneous adverse reactions were observed in 7 cases, 6 cases were grade 1, 1 case was grade 2. One patient had symptoms of palpitation, the evaluation was grade 2. All patients had mild symptoms of adverse drug reactions, but the symptoms could significantly relieve after symptomatic treatment and withdrawal of the treatment. Conclusion Temozolomide is commonly used in the treatment of malignant glioma, the toxic and side effects were observed during the process of concurrent chemoradiotherapy, the toxic and side effects were minor, and can be relieved obviously after symptomatic treatment. Therefore, temozolomide is a safe drug for malignant glioma treatment.

Key words: malignant glioma, Temozolomide, side effect